2022 ACMG Annual Clinical Genetics Meeting Digital Edition

(15)

Availability

On-Demand

3 Courses

Expires on Apr 30, 2024

Cost

ACMG Member: $349.00

Non-Member: $399.00

Postdoc/Trainee (M): $349.00

Postdoc/Trainee (NM): $399.00

Student (M): $349.00

Student (NM): $399.00

Credit Offered

46 CME (AMA) Credits

46 CME (Other) Credits

46 P.A.C.E. Credits

47.25 NSGC Credits

First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net or call 301-718-9603.

Or click on the "Help" icon on the left-hand side of your screen for more information.

Support Center Hours: Monday- Friday 9:00 am - 5:00 pm Eastern Time

Date of Release: May 2, 2022

Expiration Date: April 30, 2024

Credits offered: CME, P.A.C.E.®, NSGC

Estimate time of completion: 47 hours

Course must be completed by the expiration date and NSGC credits are reported one time.

COURSE DESCRIPTION

The 2022 ACMG Annual Clinical Genetics Meeting: Digital Edition presents both research and clinical topics that promote the science and the practice of clinical genetics and genomics. Sessions will focus on the latest discoveries of the etiology and the pathogenesis of genetic disorders, the latest developments in genetic testing and screening, the laboratory’s role in the diagnosis of genetic disorders, the treatment of genetic disorders in children and adults, the delivery of genetic services, and more.

Learning Objectives

At the conclusion of this course, participants should be able to:

Describe the advances in genetic testing including prenatal and postnatal indications, gene panels, genome sequencing, interpretation, genetic counseling, and ethical and legal issues.
Review select rare and common genetic disorders, from developmental disabilities to cancer predisposition syndromes, as well as novel therapeutic approaches including gene editing.
Review select inborn errors of metabolism, approaches to their diagnoses and treatment, new disorders on the recommended uniform screening panel.
Recognize the importance of Diversity, Equity, and Inclusion in genetic clinical care and research, and the inclusion as an essential component for genetic workforce development.
Analyze the need for innovation and new approaches to transforming the current practice of genetic medicine to achieve a vision of genomically-informed precision population health.

Target Audience

All healthcare professionals interested in the diagnosis, management, treatment, and prevention of genetic conditions and increasing their understanding of the genetic basis of common, chronic health problems affecting both children and adults will find the programming applicable to their practice. The ACMG Annual Meeting is targeted for the following professionals:

Medical and clinical geneticists; genetic counselors; pediatric, obstetric, and maternal-fetal specialists; and all medical practitioners who are providing comprehensive diagnostic, management, and counseling services for patients with, or at risk for, genetically influenced health problems
Laboratory directors and technicians who conduct genetic testing
Researchers involved in the discovery of genetic disorders and treatments
Clinical, laboratory and research trainees of genetics and all biomedical sciences
Any healthcare and public health professionals who have an in interest in medical and clinical genetics and genomics
Advocates for patients with genetic conditions and their families

Session Title	Session Type	CME	P.A.C.E.®	NSGC
Genetic Counselors Forum (NSGC Credits only)	Genetic Counselor Forum			1.25
Featured Platform Presentations	Platform	1	1	1
Platform Presentations - Biochemical/Metabolic Genetics	Platform	1.5	1.5	1.5
Platform Presentations - Cancer Genetics and Therapeutics	Platform	1.5	1.5	1.5
Platform Presentations - Clinical Genetics and Therapeutics	Platform	1.5	1.5	1.5
Platform Presentations - Genetic Counseling	Platform	1.5	1.5	1.5
Platform Presentations - Laboratory Genetics and Genomics	Platform	1.5	1.5	1.5
Platform Presentations - Legal and Ethical Issues; Education	Platform	1.5	1.5	1.5
Platform Presentations - Prenatal Genetics	Platform	1.5	1.5	1.5
Platform Presentations - Public Health, Health Services and Implementation	Platform	1.5	1.5	1.5
2022 Cardinal Signs	Concurrent	1.5	1.5	1.5
Addressing the Challenges of Variant Reinterpretation	Concurrent	1.5	1.5	1.5
Adult & Cancer Diagnostic Challenges	Concurrent	1.5	1.5	1.5
Artificial Intelligence in Genomics: Potential and Peril - A SELI-Sponsored Session	Concurrent	1.5	1.5	1.5
Balancing Evidence and Expertise: Clinical Practice Resource Development for PALB2, CHEK2, ATM and Beyond	Concurrent	1.5	1.5	1.5
Down Syndrome Regression Disorder: Phenotype and Diagnostic Evaluation	Concurrent	1.5	1.5	1.5
Exploring the Role of Medical Genetics and Genomics in Advancing Newborn Screening Research	Concurrent	1.5	1.5	1.5
Health Disparities and Inherited Cancer Syndromes	Concurrent	1.5	1.5	1.5
Hot Topics in Reproductive Genetics	Concurrent	1.5	1.5	1.5
Human Ring Chromosome Disorders: An international Collaboration Towards Better Diagnosis, Interpretations, and Clinical Management	Concurrent	1.5	1.5	1.5
Laboratory Diagnostic Challenges (Constitutional and Neoplastic Cases in Molecular, Cytogenomic, and Biochemical Genetics Specialties)	Concurrent	1.5	1.5	1.5
Prenatal Diagnostic Challenges	Concurrent	1.5	1.5	1.5
Reimagining Pediatric Genetic Service Delivery - Telemedicine Models in the Post COVID-19 Era	Concurrent	1.5	1.5	1.5
Rethinking Schwannoma Predisposition Syndromes - Neurofibromatosis Type 2 and Schwannomatosis	Concurrent	1.5	1.5	1.5
The Role of the HNRNP Gene Family in Neurodevelopmental Disorders	Concurrent	1.5	1.5	1.5
When is 'Non-Syndromic' Really Metabolic: Metabolic Causes of Intellectual Disability, Autism and Epilepsy	Concurrent	1.5	1.5	1.5
2022 Presidential Plenary Session - From Exceptional to Routine: Transformation of Genomic Medicine in the 21st Century	Plenary	1.5	1.5	1.5
Developing Recommendations for the Application of Direct-to-Consumer Genetic Testing in Clinical Care	Plenary	1.5	1.5	1.5
R. Rodney Howell Symposium \| Population Genomic Health: Expanding the Reach of Genomic Medicine to Diverse Populations	Plenary	1.5	1.5	1.5
What are the Important Issues in the Arena of Public Policy and Legislation for Medical Genetics?	Plenary	1.5	1.5	1.5
An Action Plan for Inclusion, Diversity, Equity and Anti-Racism in Publishing: Putting IDEAs into Practice at Genetics in Medicine	Workshop	1.5	1.5	1.5
The ACMG Evidence-Based Guideline Program: Our Roadmap from Evidence to Recommendations and the impact on Patient Care	Workshop	1.5	1.5	1.5
Total Credits		46	46	47.25

Continuing Medical Education (CME AMA & CME Other)
Accreditation
The American College of Medical Genetics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 46 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

P.A.C.E.^®CEU's
ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program.

ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider (50-11878). This course is registered with CEBroker #20-908432. ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®. This activity has been approved for 46 P.A.C.E.® CEU's.

National Society of Genetic Counselors (NSGC)
The National Society of Genetic Counselors (NSGC) has authorized American College of Medical Genetics and Genomics (ACMG) to offer up to 4.725 CEUs or 47.25 Category 1 contact hours for the activity 2022 ACMG Annual Clinical Genetics Meeting: Digital Edition. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

ACMG reports completed accredited sessions to NSGC for credit certificates annually.

Reporting year	Participant deadline to claim credits	ACMG reporting date
2023	12/4/2023	12/6/2023
2024	4/30/2024	05/30/2024

Participation Instructions (OnDemand)

Complete session by watching recordings.
Pass a post-test with a score of 80% or better (Learning mode activated and reset).
Complete session evaluations.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

All of the relevant financial relationships listed for these individuals have been mitigated.

Name	Program Committee Member	Presenter Panelist Moderator	Peer Reviewer	Financial Disclosure Relationship/Company
Abul-Husn, Noura		x		Scientific Medical Advisor, Allelica
Adam, Margaret		x		Nothing to disclose
Adams, Michael		x		Nothing to disclose
Aggarwal, Nidhi		x		Nothing to disclose
Akkari, Yassmine		x		Nothing to disclose
Appelbaum, Paul		x		Nothing to disclose
Astiazaran Symonds, Esteban		x		Nothing to disclose
Au, Ping Yee Billie		x		Nothing to disclose
Austin-Tse, Christina		x		Nothing to disclose
Ayoubieh, Houriya		x		Nothing to disclose
Bain, Jennifer		x		Nothing to disclose
Balasubramanian, Meena		x		Nothing to disclose
Balmaña, Judith		x		Consultant: AstraZeneca
Barnett, Claudia	x			Nothing to disclose
Barua, Subit		x		Nothing to disclose
Bastarache, Lisa		x		Nothing to disclose
Beck, Natalie		x		Nothing to disclose
Bennett, Frank		x		Employee, Stock Interests: Ionis Pharmaceuticals
Bennett, Robin		x		Nothing to disclose
Bernat, John	x			Advisory Board Member: Avrobio, BioMarin Pharmaceutical, Idorsia Pharmaceuticals, Pfizer, Protalix Biotherapeutics, Sangamo Therapeutics, Sanofi Genzyme, Takeda Pharmaceutical; Grant/Research Support: Avrobio, BioMarin Pharmaceutical, Idorsia Pharmaceuticals, Pfizer, Protalix Biotherapeutics, Sangamo Therapeutics, Sanofi Genzyme, Takeda Pharmaceutical
Berry, Susan	x	x		Reported disclosures and none are relevant to the content of this course.
Blitzer, Miriam		x		Nothing to disclose
Bird, Lynne		x		Nothing to disclose
Bodurtha, Joann		x		Nothing to disclose
Bombard, Yvonne		x		Nothing to disclose
Boychuk, Natalie		x		Nothing to disclose
Brar, Bobby		x		Nothing to disclose
Brockman, Deanna		x		Nothing to disclose
Brothers, Kyle		x		Nothing to disclose
Brower, Amy		x		Nothing to disclose
Bupp, Caleb		x		Nothing to disclose
Burke, Leah		x		Nothing to disclose
Burrow, Thomas		x		Contractor: Amicus Therapeutics, Biomarin Pharmaceutical, Sanofi, Takeda, Scientific Medical Advisor: Sanofi, Takeda
Cao, Yang		X		Nothing to disclose
Carmichael, Jason		x		Nothing to disclose
Cho, Mildred		x		Nothing to disclose
Chung, Wendy		x		Reported disclosures and none are relevant to the content of this course.
Clayton, Ellen		x		Nothing to disclose
Cochran, Meagan		x		Nothing to disclose
Conboy, Erin	x	x		Nothing to disclose
Crimi, Marco		x		Reported disclosures and none are relevant to the content of this course.
Cusmano-Ozog, Kristina	x	x		Nothing to disclose
Dahlroth, Jane	x			Nothing to disclose
D'Annibale, Olivia		x		Nothing to disclose
Dhar, Shweta		x		Reported disclosures and none are relevant to the content of this course.
DiCicco, Renee		x		Nothing to disclose
Dinulos, Mary Beth		x		Nothing to disclose
Dobin, Sheila		x		Nothing to disclose
Drackley, Andy		x		Nothing to disclose
Dugoff, Lorraine		x		Grant/Research Support, Labcorp, Natera
DuPont, Barbara		x		Nothing to disclose
Duque Lasio, Maria Laura		x		Nothing to disclose
East, Kelly		x		Nothing to disclose
Eddleman, Keith	x	x		Reported disclosures and none are relevant to the content of this course.
Edmondson, Andrew		x		Nothing to disclose
Elsea, Sarah	x	x		Grant/Research Support: Rhythm Pharmaceuticals, PTC Therapeutics, Shire Genetic Therapies Consultant: Dicerna, Enzyvant, Vanda Pharmaceuticals Rhythm Pharmaceuticals and Shire Genetic Therapies grants and Dicerna, Enzyvant consultancies have ended
Emrick, Lisa		x		Nothing to disclose
Falah, Nadia		x		Nothing to disclose
Farrow, Emily		x		Advisory Committee Member: Illumina
Fishler, Kristen		x		Nothing to disclose
Formea, Christine		x		Nothing to disclose
Freedenberg, Debra		x		Nothing to disclose
Freire, Penelope	x			Nothing to disclose
Gambello, Michael	x	x		Nothing to disclose
Ganetzky, Rebecca		x		Consultant: Minovia Therapeutics
Gillentine, Madelyn		x		Nothing to disclose
Gomes, Alicia		x		Nothing to disclose
Grebe, Theresa		x		Nothing to disclose
Gripp, Karen		x		Nothing to disclose
Gropman, Andrea		x		Nothing to disclose
Haldeman-Englert, Chad		x		Nothing to disclose
Guha, Saurav		x		Nothing to disclose
Hanson, Helen		x		Nothing to disclose
Hardy, Melanie		x		Reported disclosures and none are relevant to the content of this course.
Hiatt, Susan		x		Nothing to disclose
Hildebrandt, Clara Cornelia		x		Nothing to disclose
Hisama, Fuki		x		Nothing to disclose
Hodge, Jennelle	x			Scientific advisor: Helogenika
Hoffman, Jodi	x	x		Nothing to disclose
Hoffman, Trevor		x		Nothing to disclose
Holm, Ingrid		x		Steering committee relationship: Biomarin
Hoppman, Nicole		x		Nothing to disclose
Hunter, Jessica		x		Honoraria: Biomarin
Irving, Melita		x		Nothing to disclose
Jenkins, Gabrielle		x		Reported disclosures and none are relevant to the content of this course.
Jianling, Ji		x		Nothing to disclose
Jiang, Nan		x		Nothing to disclose
Jose, Merin		x		Nothing to disclose
Kaler, Stephen		x		Chair of Data Monitoring Committee: Vivet Therapeutics
Kantorowska, Agata		x		Nothing to disclose
Kelly, Melissa		x		Nothing to disclose
Kelly, Nicole		x		Nothing to disclose
Kenny, Eimear		x		Reported disclosures and none are relevant to the content of this course.
Khushf, George		x		Nothing to disclose
Kidd, Jennifer		x		Nothing to disclose
King, Jennifer	x	x		Nothing to disclose
Klein, Ophir		x		Nothing to disclose
Kline, Antonie		x		Nothing to disclose
Klugman, Susan		x		Nothing to disclose
Koleilat, Alaa		x		Nothing to disclose
Kopp, Nathan	x	x		Nothing to disclose
Kronn, David		x		Consultant: AskBio, Sanofi; Grant/Research Support: Sanofi; Speakers Bureau: Spark Therapeutics, Sanofi
Kulchak Rahm, Alanna	x	x		Nothing to disclose
Kurian, Allison		x		Reported disclosures and none are relevant to the content of this course.
Lancaster, Kristen		x		Nothing to disclose
Lebedev, Igor		x		Nothing to disclose
Lee, Heewon		x		Nothing to disclose
Lenberg, Jerica		x		Reported disclosures and none are relevant to the content of this course.
Lerner, Barbara		x		Nothing to disclose
Leung, Marco		x		Nothing to disclose
Li, Peining		x		Nothing to disclose
Liehr, Thomas		x		Nothing to disclose
Lombard, Zané		x		Nothing to disclose
Longo, Nicola		x		Grant/Research Support: Ultragenix; Scientific Medical Advisor: Ultragenix
Lyon, Megan		x		Nothing to disclose
Madjunkova, Svetlana		x		Nothing to disclose
Makhamreh, Mona		x		Nothing to disclose
Malinowski, Jennifer		x		Nothing to disclose
Manderski, Elizabeth		x		Nothing to disclose
Massart, Mylynda		x		Scientific Medical Advisor: Grail
McClure, Michelle		x		Reported disclosures and none are relevant to the content of this course.
McInerney, Joseph		x		Nothing to disclose
Mefford, Heather		x		Nothing to disclose
Meng, Su			x	Nothing to disclose
Messersmith, Donna		x		Nothing to disclose
Miller, Danny		x		Consultant: MyOme; Grant/Research support Oxford Nanopore Technologies
Milko, Laura		x		Nothing to disclose
Miller, Marcus		x		Nothing to disclose
Miller, Megan		x		Nothing to disclose
Mito, Yoshiko	x	x		Nothing to disclose
Mostafavi, Roya		x		Nothing to disclose
Muenke, Maximilian	x			Nothing to disclose
Mulvihill, John			x	Nothing to disclose
Muthusamy, Karthik		x		Nothing to disclose
Narang, Kavita		x		Nothing to disclose
Narula, Jahnavi		x		Nothing to disclose
Niehaus, Annie		x	x	Nothing to disclose
Niu, Nifang		x		Nothing to disclose
Nguyen, Michelle		x		Nothing to disclose
Null, Elizabeth		x		Nothing to disclose
Oglesbee, Devin		x		Nothing to disclose
O'Shea, Jessica	x	x		Nothing to disclose
Osterman, Travis		x		Grant/Research Support: Microsoft
Pal, Tuya	x	x		Nothing to disclose
Palculict, Blake		x		Nothing to disclose
Parikh, Aditi			x	Nothing to disclose
Pappas, Kara		x		Nothing to disclose
Patberg, Elizabeth		x		Nothing to disclose
Pascual, Juan		x		Nothing to disclose
Patel, Lina		x		Nothing to disclose
Paul, Lianna		x		Nothing to disclose
Pekarek, Dawn		x		Nothing to disclose
Peterson, Carly		x		Nothing to disclose
Pletcher, Beth		x		Nothing to disclose
Plon, Sharon		x		Nothing to disclose
Plotkin, Scott		x		Reported disclosures and none are relevant to the content of this course.
Popejoy, Alice		x		Nothing to disclose
Powell, Cynthia		x		Nothing to disclose
Quintero-Rivera, Fabiola		x		Nothing to disclose
Radford, Jane	x			Nothing to disclose
Regier, Debra		x		Nothing to disclose
Rehm, Heidi		x		Reported disclosures and none are relevant to the content of this course.
Reid, Sonya		x		Reported disclosures and none are relevant to the content of this course.
Rezich, Brianna		x		Nothing to disclose
Riggan, Kirsten		x		Nothing to disclose
Rohanizadegan, Mersedeh		x		Nothing to disclose
Rose, Nancy		x		Nothing to disclose
Rowsey, Ross	x	x		Nothing to disclose
Sack, Laura		x		Reported disclosures and none are relevant to the content of this course
Santoro, Jonathan		x		Nothing to disclose
Santoro, Stephanie		x		Nothing to disclose
Scheuner, Maren		x		Nothing to disclose
Schindler, Karen		x		Nothing to disclose
Sellers, Heidi		x		Nothing to disclose
Sen, Kuntal		x		Nothing to disclose
Shaw, Brandon		x		Nothing to disclose
Shieh, Perry		x		Grant/Research Support: Alexion, Argenx, Audentes Therapeutics, AveXis, Biogen, Catalyst Pharmaceuticals, CSL Behring, Fulcrum Therapeutics, Grifols, S.A., Pfizer, PTC Therapeutics, Ra Pharma, Roche, Sarepta Therapeutics
Sheridan, Nina		x		Nothing to disclose
Similuk, Morgan		x		Nothing to disclose
Slavotinek, Anne			x	Nothing to disclose
Solomon, Benjamin		x		Reported disclosures and none are relevant to the content of this course.
Stander, Zinandre		x		Nothing to disclose
Stergachis, Andrew		x		Nothing to disclose
Stewart, Douglas		x		Reported disclosures and none are relevant to the content of this course.
Stover, Samantha	x	x		Nothing to disclose
Strauss, Tirtza Spiegel		x		Nothing to disclose
Summar, Marshall		x		Nothing to disclose
Taylor, Jennifer		x		Nothing to disclose
Taylor, Mathew		x		Nothing to disclose
Timp, Winston		x		Patent Beneficiary: Oxford Nanopore Technologies
Tischkowitz, Marc	x	x		Nothing to disclose
Turley, Patrick		x		Nothing to disclose
Turnwald, Abigail		x		Nothing to disclose
Van Karnebek, Clara		x		Nothing to disclose
Vieira Neto, Eduardo		x		Nothing to disclose
Viskochil, David		x		Reported disclosures and none are relevant to the content of this course.
Vockley, Jerry		x		Consultant: Acer Therapeutics, Agios Pharmaceuticals, American Gene Technologies International, Applied Therapeutics Aro Biotherapeutics, Axcella Health, BioMarin Pharmaceutical Horizon Therapeutics, Illumina , Logicbio Therapeutics, Orphan Labs, Sangamo Therapeutics, Sanofi, SatelliteBio, Symlogic; Stock Holder: Axcella Health
Weiler, Tracey		x		Nothing to disclose
Wenger, Tara		x		Nothing to disclose
Wick, Myra	x	x		Nothing to disclose
Wigby, Kristen		x		Reported disclosures and none are relevant to the content of this course.
Wildin, Robert		x		Nothing to disclose
Williams, Eli	x	x		Nothing to disclose
Williams, Marc	x	x		Nothing to disclose
Willis, Valerie		x		Nothing to disclose
Wojcik, Genevieve		x		Nothing to disclose
Wojcik, Monica		x		Reported disclosures and none are relevant to the content of this course.
Wolfgang, Morgan		x		Nothing to disclose
Wong, Derek		x		Nothing to disclose
Wynshaw-Boris, Anthony		x		Nothing to disclose
Yano, Sho		x		Nothing to disclose
Yohay, Kaleb		x		Consultant: AstraZeneca
Yu, Christine		x		Nothing to disclose
Zarate, Yuri		x		Nothing to disclose
Zemet Lazar, Roni		x		Nothing to disclose
Zepeda Mendoza, Cinthya	x	x		Nothing to disclose
Zhao, Boxun		x		Nothing to disclose
Zhao, Jian		x		Nothing to disclose
Zhou, Alicia		x		Employee: Color Health